Skip to main content
. 2023 Aug 10;17(9):851–864. doi: 10.1111/crj.13670

TABLE 1.

Baseline characteristics of participants to doxophylline group and non‐doxophylline group.

Parameters

Non‐doxophylline group

(n = 87)

Doxophylline group

(n = 68)

Total P value
Gender (n, %) 0.881
Male 45 (51.7%) 36 (52.9%) 81 (52.3%)
Female 42 (48.3%) 32 (47.1%) 74 (47.7%)
Age (year) b 72.5 ± 9.3 69.5 ± 10.3 71.2 ± 10.1 0.073
BMI (kg/m2) b 22.5 22.8 22.6 0.215
Smoking (n, %) 45 (51.7%) 42 (61.8%) 87 (56.1%) 0.211
Age of smoking 28.0 26.5 27.0 0.895
Smoking index b 700.0 600.0 600.0 0.149
Length of diagnosis b 8.0 9.0 8.0 0.899
Exacerbations in last 1 year 0.8 ± 0.7 0.8 ± 1.7 0.8 ± 1.2 0.887
Comorbidities (n, %)
Hypertension/coronary heart disease 62 (71.3%) 46 (67.6%) 108 (69.7%) 0.627
Cor pulmonale 6 (6.9%) 5 (7.4%) 11 (7.1%) 0.913
Digestive system diseases 10 (11.5%) 8 (11.8%) 18 (11.6%) 0.958
Diabetes 15 (17.2%) 11 (16.2%) 26 (16.8%) 0.860
Cerebrovascular diseases 9 (10.3%) 6 (8.8%) 15 (9.7%) 0.751
GOLD stage (n, %)
Level 1 2 (2.3%) 2 (2.9%) 4 (2.6%)
Level 2 23 (26.4%) 14 (20.6%) 37 (23.9%) 0.371
Level 3 41 (47.1%) 27 (39.1%) 68 (43.9%)
Level 4 21 (24.1%) 25 (36.8%) 46 (29.7%)
FEV1% predicted b 41.0 36.0 38.0 0.091
MEF% b 29.0 27.0 27.0 0.075
mMRC dyspnea score (n, %)
1: Breathless hurrying 2 (2.3%) 2 (2.9%) 4 (2.6%) 0.627
2: Slower than contemporaries 19 (21.8%) 15 (22.1%) 34 (21.9%)
3: Stop after 100 m 44 (50.6%) 28 (41.2%) 72 (46.5%)
4: Breathless leaving house 22 (25.3%) 23 (33.8%) 45 (29.0%)
COPD assessment test scole (CAT) 22.5 ± 2.8 22.7 ± 2.6 22.6 ± 2.7 0.615
GOLD treatment (n, %)
LAMA only 16 (18.4%) 14 (20.6%) 30 (19.4%) 0.114
LAMA + ICS 38 (43.7%) 32 (47.1%) 70 (45.2%) 0.089
LABA + ICS 13 (14.9%) 8 (11.8%) 21 (13.5%) 0.916
LAMA + LABA + ICS 20 (23.0%) 14 (20.6%) 34 (21.9%) 0.181
Leukocyte a (10^9/L) 8.6 ± 3.8 8.4 ± 3.2 8.5 ± 3.5 0.984
Neutrophil percentage b (%) 69.7 67.7 68.5 0.580
Lymphocyte percentage b (%) 20.2 20.5 20.2 0.892
Eosinophil percentage b (%) 2.2 1.5 1.5 0.445
Clinical phenotypes (n, %) 0.346
Neutrophilic 43 (49.4%) 33 (48.5%) 76 (49.0%)
Eosinophilic 12 (13.8%) 15 (22.1%) 27 (17.4%)
Mixed granulocytic 32 (36.8%) 20 (29.4%) 52 (33.5%)
Combined with rheumatological conditions (n, %) 0 (0.0%) 0 (0.0%) 0 (0.0%) >0.999
Mandated use of corticosteroids or recently corticosteroids used 0 (0.0%) 0 (0.0%) 0 (0.0%) >0.999

Note: Counting data are expressed in frequency and percentage (n, %).

a

Mean ± SD.

b

Median (interquartile range).